Read Time:11 Second
IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating